Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Patients who received 3 doses of pembrolizumab before surgery and 15 doses after surgery had significantly longer event-free survival than those who received adjuvant-only therapy with 18 doses after surgery.

Uloženo v:

Podrobná bibliografie
Vydáno v:	The New England journal of medicine Ročník 388; číslo 9; s. 813 - 823
Hlavní autoři:	Patel, Sapna P., Othus, Megan, Chen, Yuanbin, Wright, G. Paul, Yost, Kathleen J., Hyngstrom, John R., Hu-Lieskovan, Siwen, Lao, Christopher D., Fecher, Leslie A., Truong, Thach-Giao, Eisenstein, Jennifer L., Chandra, Sunandana, Sosman, Jeffrey A., Kendra, Kari L., Wu, Richard C., Devoe, Craig E., Deutsch, Gary B., Hegde, Aparna, Khalil, Maya, Mangla, Ankit, Reese, Amy M., Ross, Merrick I., Poklepovic, Andrew S., Phan, Giao Q., Onitilo, Adedayo A., Yasar, Demet G., Powers, Benjamin C., Doolittle, Gary C., In, Gino K., Kokot, Niels, Gibney, Geoffrey T., Atkins, Michael B., Shaheen, Montaser, Warneke, James A., Ikeguchi, Alexandra, Najera, Jose E., Chmielowski, Bartosz, Crompton, Joseph G., Floyd, Justin D., Hsueh, Eddy, Margolin, Kim A., Chow, Warren A., Grossmann, Kenneth F., Dietrich, Eliana, Prieto, Victor G., Lowe, Michael C., Buchbinder, Elizabeth I., Kirkwood, John M., Korde, Larissa, Moon, James, Sharon, Elad, Sondak, Vernon K., Ribas, Antoni
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Massachusetts Medical Society 02.03.2023
Témata:	Adjuvants Adjuvants, Immunologic Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Biopsy Cancer therapies Chemotherapy, Adjuvant Coronaviruses COVID-19 Dermatology Disease Progression Hematology HIV Human immunodeficiency virus Humans Immunotherapy Lymphocytes Melanoma Melanoma - drug therapy Melanoma - pathology Melanoma - surgery Metastasis Monoclonal antibodies Neoadjuvant Therapy Oncology Patients Pembrolizumab Radiation therapy Review boards Skin Cancer Skin Neoplasms - drug therapy Skin Neoplasms - pathology Skin Neoplasms - surgery Surgery Surgery General Surgical outcomes Survival Targeted cancer therapy Treatments in Oncology
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Patients who received 3 doses of pembrolizumab before surgery and 15 doses after surgery had significantly longer event-free survival than those who received adjuvant-only therapy with 18 doses after surgery.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2211437